AR116395A2 - 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida, su monohidrato o sal en una forma de pureza alta - Google Patents

4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida, su monohidrato o sal en una forma de pureza alta

Info

Publication number
AR116395A2
AR116395A2 ARP190102596A ARP190102596A AR116395A2 AR 116395 A2 AR116395 A2 AR 116395A2 AR P190102596 A ARP190102596 A AR P190102596A AR P190102596 A ARP190102596 A AR P190102596A AR 116395 A2 AR116395 A2 AR 116395A2
Authority
AR
Argentina
Prior art keywords
amino
monohydrate
salt
high purity
trifluorometil
Prior art date
Application number
ARP190102596A
Other languages
English (en)
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44070712&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR116395(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of AR116395A2 publication Critical patent/AR116395A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Abstract

Reivindicación 1: El compuesto de fórmula (1), su monohidrato o sal en una forma de pureza alta, estando el compuesto de fórmula (1), su monohidrato o sal, contaminado con una o más sustancias anilínicas, cada una en una cantidad de desde 0,0001% hasta un máximo del 0,05% en peso basado en la cantidad del compuesto de fórmula (1).
ARP190102596A 2010-04-15 2019-09-13 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida, su monohidrato o sal en una forma de pureza alta AR116395A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10004022 2010-04-15

Publications (1)

Publication Number Publication Date
AR116395A2 true AR116395A2 (es) 2021-05-05

Family

ID=44070712

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP110100982A AR081060A1 (es) 2010-04-15 2011-03-23 Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
ARP190102596A AR116395A2 (es) 2010-04-15 2019-09-13 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida, su monohidrato o sal en una forma de pureza alta

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP110100982A AR081060A1 (es) 2010-04-15 2011-03-23 Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida

Country Status (39)

Country Link
US (5) US8748622B2 (es)
EP (1) EP2558448B1 (es)
JP (1) JP5934182B2 (es)
KR (2) KR20170129276A (es)
CN (2) CN103980191A (es)
AR (2) AR081060A1 (es)
AU (1) AU2011240113B2 (es)
BR (1) BR112012026117B1 (es)
CA (1) CA2796238C (es)
CL (1) CL2012002840A1 (es)
CO (1) CO6630136A2 (es)
CR (1) CR20120526A (es)
CU (2) CU24123B1 (es)
DK (1) DK2558448T3 (es)
DO (2) DOP2012000268A (es)
EC (1) ECSP12012234A (es)
ES (1) ES2542610T3 (es)
GT (1) GT201200280A (es)
HK (1) HK1200831A1 (es)
HR (1) HRP20150885T1 (es)
HU (1) HUE026821T2 (es)
IL (2) IL222348B (es)
JO (1) JO3158B1 (es)
MA (1) MA34156B1 (es)
MX (1) MX2012011734A (es)
MY (2) MY162359A (es)
NZ (1) NZ602997A (es)
PE (2) PE20160838A1 (es)
PL (1) PL2558448T3 (es)
PT (1) PT2558448E (es)
RS (1) RS54219B1 (es)
RU (1) RU2581585C2 (es)
SG (2) SG184172A1 (es)
SI (1) SI2558448T1 (es)
TN (1) TN2012000492A1 (es)
TW (2) TWI539951B (es)
UA (1) UA110613C2 (es)
UY (2) UY33290A (es)
WO (1) WO2011128261A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8877933B2 (en) * 2004-09-29 2014-11-04 Bayer Intellectual Property Gmbh Thermodynamically stable form of a tosylate salt
WO2006094626A1 (en) 2005-03-07 2006-09-14 Bayer Healthcare Ag Pharmaceutical composition comprising an omega- carboxyaryl substituted diphenyl urea for the treatment of cancer
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
JO3479B1 (ar) * 2012-09-06 2020-07-05 Bayer Healthcare Llc تركيبة دوائية مغلفة تحتوي على ريجورافنيب
PT2900269T (pt) 2012-09-25 2018-10-22 Bayer Pharma AG Combinação de regorafenib e ácido acetilsalicílico para o tratamento de cancro colorretal
CN104250227A (zh) * 2013-06-29 2014-12-31 广东东阳光药业有限公司 瑞戈非尼新晶型及其制备方法
IN2013CH04511A (es) * 2013-10-04 2015-04-10 Hetero Research Foundation
CN105218439B (zh) * 2014-06-06 2018-11-20 连云港润众制药有限公司 一种瑞格非尼的晶体及其制备方法
WO2016005874A1 (en) * 2014-07-09 2016-01-14 Shilpa Medicare Limited Process for the preparation of regorafenib and its crystalline forms
CN104557689B (zh) * 2015-01-26 2016-06-29 重庆两江药物研发中心有限公司 制备4-[4-({[4-氯-3-(三氟甲基)苯基]氨基甲酰}氨基)-3-氟苯氧基]-n-甲基吡啶-2-甲酰胺及其一水合物的方法
CN104592105B (zh) * 2015-02-10 2017-01-18 杭州朱养心药业有限公司 瑞戈非尼及其制法
CN105330600B (zh) * 2015-11-30 2018-05-22 山东罗欣药业集团股份有限公司 一种瑞戈菲尼的制备方法
SG11201806116SA (en) * 2016-01-18 2018-08-30 Natco Pharma Ltd An improved process for the preparation of regorafenib
CN107118153A (zh) * 2016-02-25 2017-09-01 石药集团中奇制药技术（石家庄）有限公司 一种瑞戈非尼一水合物晶型及其制备方法
CN105879049B (zh) * 2016-05-13 2019-03-26 浙江大学 一种瑞戈非尼与β-环糊精的包合物及其制备方法
AU2018276273B2 (en) 2017-06-02 2023-12-21 Bayer Healthcare Llc Combination of regorafenib and PD-1/PD-L1(2) inhibitors for treating cancer
CN109438337B (zh) * 2018-11-27 2019-08-09 广东安诺药业股份有限公司 一种瑞戈非尼中间体的制备工艺
CN109438336B (zh) * 2018-11-27 2019-11-22 广东安诺药业股份有限公司 一种瑞戈非尼水合物的制备方法
EP3861989A1 (en) 2020-02-07 2021-08-11 Bayer Aktiengesellschaft Pharmaceutical composition containing regorafenib and a stabilizing agent
WO2021160708A1 (en) 2020-02-14 2021-08-19 Bayer Aktiengesellschaft Combination of regorafenib and msln-ttc for treating cancer

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6187799B1 (en) 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
US7329670B1 (en) 1997-12-22 2008-02-12 Bayer Pharmaceuticals Corporation Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
US7517880B2 (en) 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
US20080269265A1 (en) 1998-12-22 2008-10-30 Scott Miller Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas
WO2000042012A1 (en) 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
US7351834B1 (en) 1999-01-13 2008-04-01 Bayer Pharmaceuticals Corporation ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
IL144144A0 (en) 1999-01-13 2002-05-23 Bayer Ag Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7235576B1 (en) 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7371763B2 (en) 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
MXPA04005137A (es) 2001-12-03 2005-06-03 Bayer Pharmaceuticals Corp Compuestos de aril urea en combinacion con otros agentes citostaticos para el tratamiento de canceres humanos.
US10653684B2 (en) 2002-02-11 2020-05-19 Bayer Healthcare Llc Aryl ureas with angiogenisis inhibiting activity
JP4527401B2 (ja) 2002-02-11 2010-08-18 バイエル、ファーマシューテイカルズ、コーポレイション キナーゼ阻害剤としてのアリール尿素
AU2003209119A1 (en) 2002-02-11 2003-09-04 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
JP4636486B2 (ja) 2002-02-11 2011-02-23 バイエル、ファーマシューテイカルズ、コーポレイション 脈管形成阻害活性を有するアリール尿素
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
ES2305808T3 (es) 2003-05-20 2008-11-01 Bayer Healthcare Llc Diarilureas con actividad inhibidora de quinasas.
CL2004001834A1 (es) 2003-07-23 2005-06-03 Bayer Pharmaceuticals Corp Compuesto 4-{4-[3-(4-cloro-3-trifluorometilfenil)-ureido]-3-fluorofenoxi}-piridin-2-metilamida, inhibidor de la raf, vegfr, p38 y pdgfr quinasas, sus sales; composiicon farmaceutica; combinacion farmaceutica; y su uso para tratar trastornos hiperprol
MXPA06012394A (es) 2004-04-30 2007-01-31 Bayer Pharmaceuticals Corp Derivados de pirazolilurea sustituidos utiles en el tratamiento de cancer.
MY191349A (en) * 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
MX2007002398A (es) 2004-08-27 2007-05-15 Bayer Pharmaceuticals Corp Nuevas composiciones farmaceuticas para el tratamiento de cancer.
US8877933B2 (en) 2004-09-29 2014-11-04 Bayer Intellectual Property Gmbh Thermodynamically stable form of a tosylate salt
UA90691C2 (en) 2004-09-29 2010-05-25 Баер Шеринг Фарма Акциенгезельшафт Process for the preparation of 4-{ 4-[({ [4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-n-methylpyridine-2-carboxamide
WO2006094626A1 (en) 2005-03-07 2006-09-14 Bayer Healthcare Ag Pharmaceutical composition comprising an omega- carboxyaryl substituted diphenyl urea for the treatment of cancer
CA2627873A1 (en) 2005-10-31 2007-05-10 Scott Wilhelm Treatment of cancer with sorafenib
WO2007059154A2 (en) 2005-11-14 2007-05-24 Bayer Healthcare Llc Treatment of cancers with acquired resistance to kit inhibitors
AR062927A1 (es) * 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
WO2008055629A1 (en) * 2006-11-09 2008-05-15 Bayer Schering Pharma Aktiengesellschaft Polymorph iii of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide
WO2008058644A1 (en) * 2006-11-14 2008-05-22 Bayer Schering Pharma Aktiengesellschaft Polymorph ii of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide
US8101773B2 (en) 2006-12-20 2012-01-24 Bayer Healthcare Llc Hydroxy methyl phenyl pyrazolyl urea compounds useful in the treatment of cancer
CA2675980C (en) 2007-01-19 2016-06-21 Bayer Healthcare Llc Use of dast for treatment of cancers with acquired resistance to kit inhibitors
JP2010516692A (ja) 2007-01-19 2010-05-20 バイエル・ヘルスケア・エルエルシー 化学療法剤に対し抵抗性を有する癌の処置
EP2156834A1 (en) * 2008-08-08 2010-02-24 S.I.F.I - Società Industria Farmaceutica Italiana - S.P.A. Ophthalmic pharmaceutical compositions comprising Sorafenib for the treatment of neoangiogenic pathologies of the eye
US20110257035A1 (en) 2008-10-21 2011-10-20 Bayer Healthcare Llc Identification of signature genes associated with hepatocellular carcinoma
AU2010247397B2 (en) 2009-05-15 2012-07-12 Novartis Ag Combination of a phosphoinositide 3-kinase inhibitor and an antidiabetic compound
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
JP2013531067A (ja) 2010-07-19 2013-08-01 バイエル ヘルスケア リミティド ライアビリティ カンパニー 疾病及び状態の処置及び予防のためのフルオロ置換オメガ−カルボキシアリールジフェニル尿素を用いた組み合わせ薬
KR20130099117A (ko) 2010-10-01 2013-09-05 바이엘 인텔렉쳐 프로퍼티 게엠베하 치환된 ｎ-(2-아릴아미노)아릴 설폰아미드 함유 배합물
CA2840491A1 (en) 2011-06-28 2013-01-03 Bayer Healthcare Llc Topical ophthalmological pharmaceutical composition containing sorafenib
PE20141031A1 (es) 2011-06-28 2014-08-21 Bayer Healthcare Llc Composicion farmaceutica oftalmologica topica que contiene regorafenib
US8841500B2 (en) 2011-11-08 2014-09-23 Chevron U.S.A. Inc. Preparation of alkyl aromatic compounds
JP2014032346A (ja) 2012-08-06 2014-02-20 Japan Display Inc 液晶表示パネル
JO3479B1 (ar) 2012-09-06 2020-07-05 Bayer Healthcare Llc تركيبة دوائية مغلفة تحتوي على ريجورافنيب

Also Published As

Publication number Publication date
KR101800041B1 (ko) 2017-11-21
US20170334857A1 (en) 2017-11-23
MA34156B1 (fr) 2013-04-03
PE20160838A1 (es) 2016-09-24
BR112012026117B1 (pt) 2022-08-30
AU2011240113B2 (en) 2014-12-18
TW201204356A (en) 2012-02-01
CU20140060A7 (es) 2014-10-02
IL222348A0 (en) 2012-12-31
CU20120147A7 (es) 2013-01-30
UY39590A (es) 2022-01-31
ECSP12012234A (es) 2012-11-30
MX2012011734A (es) 2012-12-17
DOP2016000285A (es) 2016-11-30
PL2558448T3 (pl) 2015-10-30
SG184172A1 (en) 2012-11-29
IL253119A0 (en) 2017-08-31
TWI475992B (zh) 2015-03-11
US20140221661A1 (en) 2014-08-07
SG10201501221UA (en) 2015-04-29
US20190144391A1 (en) 2019-05-16
GT201200280A (es) 2014-07-23
NZ602997A (en) 2014-10-31
US9458107B2 (en) 2016-10-04
US20130116442A1 (en) 2013-05-09
CN103980191A (zh) 2014-08-13
CA2796238C (en) 2019-12-31
CL2012002840A1 (es) 2013-01-18
ES2542610T3 (es) 2015-08-07
HRP20150885T1 (hr) 2015-10-09
AR081060A1 (es) 2012-06-06
RS54219B1 (en) 2015-12-31
JP5934182B2 (ja) 2016-06-15
AU2011240113A1 (en) 2012-10-11
BR112012026117A8 (pt) 2017-12-19
US20170057918A1 (en) 2017-03-02
CN102947271B (zh) 2016-11-09
CU24123B1 (es) 2015-08-27
UA110613C2 (uk) 2016-01-25
EP2558448A1 (en) 2013-02-20
CN102947271A (zh) 2013-02-27
PT2558448E (pt) 2015-09-01
MY162359A (en) 2017-06-15
KR20170129276A (ko) 2017-11-24
MY177066A (en) 2020-09-03
JO3158B1 (ar) 2017-09-20
TWI539951B (zh) 2016-07-01
HK1200831A1 (en) 2015-08-14
CO6630136A2 (es) 2013-03-01
PE20130181A1 (es) 2013-02-23
WO2011128261A1 (en) 2011-10-20
DK2558448T3 (en) 2015-08-24
EP2558448B1 (en) 2015-05-20
DOP2012000268A (es) 2012-12-15
UY33290A (es) 2011-12-01
SI2558448T1 (sl) 2015-11-30
TN2012000492A1 (en) 2014-04-01
HUE026821T2 (en) 2016-07-28
US10822305B2 (en) 2020-11-03
IL253119B (en) 2018-03-29
IL222348B (en) 2018-08-30
JP2013523851A (ja) 2013-06-17
CA2796238A1 (en) 2011-10-20
RU2012148386A (ru) 2014-05-20
CR20120526A (es) 2013-03-11
RU2581585C2 (ru) 2016-04-20
KR20130061670A (ko) 2013-06-11
US8748622B2 (en) 2014-06-10
BR112012026117A2 (pt) 2015-09-08
TW201509415A (zh) 2015-03-16

Similar Documents

Publication Publication Date Title
AR116395A2 (es) 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida, su monohidrato o sal en una forma de pureza alta
MX351513B (es) Compuesto de alquinilbenceno 3,5-disustituido y sales del mismo.
UA109924C2 (uk) Аміди аміноінданів, які мають високу фунгіцидну активність та їх фітосанітарна композиція
CR20150078A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
RS54730B1 (sr) Inhibitori beta sekretaze
MY184978A (en) Pyridin-2-amides useful as cb2 agonists
MX2013012542A (es) Compuestos de amida y aplicacion farmaceutica para el mismo.
MX365744B (es) Derivados de sulfuro de trifluoroetilo o sustituidos con n-arilamidina como acaricidas e insecticidas.
UA110880C2 (uk) Заміщені амідином бета-лактами, їх одержання та застосування як антибактеріальних засобів
MY163187A (en) Novel imidazo-oxazine compound or salt thereof
UA114611C2 (uk) Пестицидні композиції і способи, що їх стосуються
MX351812B (es) Derivados de piridona.
UY34365A (es) Compuestos heterociclicos
MA32383B1 (fr) DÉRIVÉS D'INDAZOLES à SUBSTITUTIONS PHÉNYLE ET BENZODIOXYNYLE
EA201270216A1 (ru) Фармацевтический состав
UY34442A (es) 2-tiopirimidinonas.
CY1118883T1 (el) Μεθοδος παρασκευης βορτιοξετινης
AU2012310674B2 (en) Radioactive fluorine labeled compound
EA201592268A1 (ru) Дигидропиридиноновые ингибиторы mgat2
PH12015502665A1 (en) Improvements in or relating to organic compounds
EA201590250A1 (ru) Производные карбамат/мочевины
GB201305247D0 (en) Amide Compounds
EP2585455A4 (en) COMPOUNDS AND THEIR USE IN THE MODULATION OF THE CONCENTRATIONS OF VARIOUS AMYLOID BETA PEPTIDE ALLOYS
PH12015501146A1 (en) Hydantoin derivative
EA201600123A1 (ru) Производные 1-(пиперазин-1-ил)-2-([1,2,4]триазол-1-ил)этанона